This study is testing whether adding the antiviral drug valganciclovir to standard glioblastoma treatment helps patients live longer. It involves 220 adults with newly diagnosed glioblastoma who will receive either the antiviral or a placebo alongside their standard chemotherapy …
Phase: PHASE2 • Sponsor: Cecilia Soderberg-Naucler • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC